Details:
ALZ-101 is a vaccine that stimulates the production of antibodies against the toxic Aβ oligomers. It has completed the preclinical phase. A first-in-human study in patients with early Alzheimer’s disease is about to start.
Lead Product(s): ALZ-101
Therapeutic Area: Neurology Product Name: ALZ-101
Highest Development Status: IND Enabling Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2021